Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.

Authors

Publication Details

Journal
Figshare
Published
2026-11-18
DOI
https://doi.org/10.6084/m9.figshare.35049871
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

MPH Katie Lewis, Luis Hernandez, Alicia Cerretani, Amber Simpson et al.
3 links
Figshare
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Real-world hematocrit control, burden of phlebotomy, and quality of life in patients with polycythemia vera treated with phlebotomy in the United States: results from a real-world survey

MPH Katie Lewis, Luis Hernandez, Alicia Cerretani, Amber Simpson, Kristen Pettit, Chloe Hall, Angela Qi Fan
article en

Abstract

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis. Therapeutic phlebotomy is widely used in PV care, aimed to lower hematocrit levels to <45%. This study aimed to assess the real-world burden of phlebotomy and patient quality of life (QoL). Data were drawn from the Adelphi Real World PV Disease Specific Programme™, a cross-sectional survey with retrospective data collection, in patients with PV and their treating physicians in the U.S. between August 2025 and February 2026. Thirty-nine physicians reported data for 160 patients; 97 had received a phlebotomy in the 12 months prior to the survey (23 frequent phlebotomy; 74 infrequent phlebotomy). Most (91.5%) had uncontrolled hematocrit levels, defined as ≥1 test ≥45%, and no significant association was found between hematocrit control and phlebotomy frequency. Fatigue was commonly reported as a phlebotomy side effect (69.1%) and as a symptom (19.6%), and the median PROMIS Fatigue score was 56.6 (48.1, 61.1). Median activity impairment on the WPAI was 30.0% (20.0, 65.0). Current treatments, including phlebotomy (with or without cytoreductive therapy), may not adequately control hematocrit or symptoms, and impair QoL. This highlights a need for treatment strategies that offer control over hematocrit and symptoms while improving QoL.

Figshare
Good health and well-being
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon